Log in with Facebook

Log in with emailForgot password?


Join with Facebook



Timothy A. Jamieson, MD, PhD is a practicing radiation oncologist specializing in CyberKnife stereotactic radiosurgery and has been both an investor and active participant in several biotech start-ups.

He received his B.S. in Chemical Engineering from Penn State and M.D. and Ph.D. in Molecular Biology from the University of Virginia. Dr. Jamieson completed his Radiation Oncology residency at Duke University Medical Center where he won the American Radium Society's Young Oncologist Award for his research in tumor suppressor genes in head and neck cancer. He is medical director of the Cancer Care Center and the CyberKnife Center at Southeast Georgia Health System in Brunswick, GA, and is a Clinical Associate Professor with the Medical College of Georgia.

Dr. Jamieson is Chief Medical Officer for Palmetto Pharmaceuticals which has licensed an over-the-counter sustained release L-arginine drug used in cardiovascular disease prevention. Palmetto has extensive Intellectual Property in the use of statins in cardiovascular risk reduction and is currently involved in the licensing of this IP. The company is also developing a polymerized statin cardiac stent. Tim is also involved in FirstString research, a Charleston, SC-based biotech company specializing in wound repair and radiation injury.

Dr. Jamieson, a native of Boiling Springs, PA, resides in St. Simons Island, GA with his wife and 4 children ages 8 to 16.

Site Disclaimer

RedCrow.com is operated by Red Crow Crowd, Inc. By using this Site, you are subject to our Terms of Use and our Privacy Policy. Please read these carefully before proceeding. Our Site offers investors the opportunity to invest in early-stage companies through JumpStart Securities, LLC, a non-affiliated registered broker/dealer and FINRA/SIPC member. RedCrow does not affect securities transactions, give investment advice or recommend any securities. RedCrow is not registered as a broker-dealer, funding portal or investment adviser. RedCrow is not a fiduciary capacity with respect to any user of our services. We do not make recommendations regarding the appropriateness of particular opportunity for any particular investor. Investors must make their own investment decisions, either alone or with their personal advisors. Investing in early-stage companies can be risky and unpredictable. Many early-stage businesses fail to meet expectations or fail altogether. You shouldn’t expect the companies you see on our Site to be the next Facebook or Google. By definition, most early-stage companies are trying to do something that’s never been done before, inventing a product that consumers have never seen before, and/or competing against — and trying to undercut — an established business model. That’s risky, and according to Forbes, 90% of startups fail. The companies listed on our Site may provide financial projections for some of the investment opportunity. All such financial projections are only estimates based on current conditions and current assumptions. The actual result of any investment is likely to be different than the original projection, often by a large amount. Neither we nor anyone else guaranties the results reflected in financial projections. All of the information provided by companies listed on our site has been provided by, and is the responsibility of, the listed company. Neither the Securities and Exchange Commission nor any state agency has reviewed the investment opportunities listed on the Site. If you decide to invest in a company listed on our site, your investment will be effected through JumpStart Securities, LLC, a registered broker/dealer and member of FINRA/SIPC. JumpStart Securities, LLC is compensated for its services in connection with the listed company’s securities offering. JumpStart Securities, LLC does not make securities recommendations. Thank you for using the Site. If you have questions, please contact us at info@redcrow.com.